search
Back to results

Feeding Bovine Colostrum to Preterm Infants (PreColos)

Primary Purpose

Feeding Intolerance, Extrauterine Growth Retardation, Necrotizing Enterocolitis

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Bovine colostrum
Sponsored by
Per Torp Sangild
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Feeding Intolerance focused on measuring Preterm infants, Bovine colostrum, Feeding intolerance, Postnatal growth, Intestinal maturation, Necrotizing enterocolitis

Eligibility Criteria

undefined - 1 Day (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • FWCH & SBMCH: Preterm infants with birth weights between 1000 and 1800 g, delivered at FWCH & SBMCH, or transferred from other hospitals within 24 h of birth and without any enteral feeding.

RH & HH: Preterm infants less than 24 hours of age, between 27+0 and 32+6 weeks of gestation, delivered at RH &HH , or transferred from other hospitals within the first 24 h after birth.

  • Signed parental consent

Exclusion Criteria:

  • Major congenital anomalies or birth defects
  • Congenital infection
  • Perinatal asphyxia
  • Gestational age at birth < 28 weeks (FWCH & SBMCH)
  • Extremely SGA infant (weight SD score < -3 SD)
  • Need for mechanical ventilation or cardiovascular support before first BC feeding

Sites / Locations

  • Foshan Women and Children's Hospital (FWCH)
  • Shenzheng Baoan Maternity and Child Healthcare Hospital (SBMCH)
  • Rigshospitalet (RH)
  • Hvidovre Hospital (HH)

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control group

Colostrum group

Arm Description

Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).

Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.

Outcomes

Primary Outcome Measures

The primary outcome is the tolerability of bovine colostrum feeding
The main purpose of this feasibility pilot study is to investigate whether preterm infants can tolerate bovine colostrum as their first nutrition supplemented to mother's own milk (if available). Presence of feeding intolerance is defined as at any time when feeding is withheld by the neonatologists from day 1-7 and from day 8-14.

Secondary Outcome Measures

Anthropometry data
Body weight, body length, and head circumference are measured as anthropometry data
Days to regain birth weight
Days on parenteral nutrition
Days on PN are the total number of days that a participant receiving any i.v. nutrients other than glucose.
Time to full enteral feeding
Full enteral feeding is defined as participants receiving 160ml/kg/d at copenhagen site, or more than 120 ml/kg/d at Chinese sites for a consecutive period of 72 hours.
Combined incidence of serious infections and NEC
Serious infections/NEC includes sepsis and meningitis, according the diagnostic criteria at each hospital, and Bell stage II or III NEC.
Plasma citrulline level
Citrulline concentration is measured in plasma as a biomarker for absorptive enterocyte mass and/or function
Lactase activity and intestinal permeability
Lactase activity and intestinal permeability is measured non-invasively by measuring the urinary ratio of lactulose/lactose, and lactulose/mannitol after the three sugars are administered.

Full Information

First Posted
January 21, 2014
Last Updated
January 17, 2019
Sponsor
Per Torp Sangild
search

1. Study Identification

Unique Protocol Identification Number
NCT02054091
Brief Title
Feeding Bovine Colostrum to Preterm Infants
Acronym
PreColos
Official Title
Bovine Colostrum as Nutrition for Preterm Infants in the First Days of Life: A Pilot Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
February 2014 (Actual)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Per Torp Sangild

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Feeding preterm infants is of great challenge in the NICUs. Mother's own milk is considered as the best for the digestive system followed by donor milk. Preterm infant formula is related to more feeding problems and other gut complications in these babies, such as necrotizing enterocolitis. Bovine colostrum contains higher amounts of protein, growth factors and immuno-regulatory components (e.g. immunoglobulins), which has been used in many other situations to promote health. The investigators plan to give bovine colostrum to preterm infants with birth weights between 1000 and 1800 g, or born between 27+0 and 32+6 weeks of gestational age, in order to promote feeding and intestinal health in these babies. This current study is a feasibility pilot study and the investigators hypothesized that supplementing BC to MM (if available) is safe and tolerable when used within the first 10-14 days of life in preterm infants.
Detailed Description
Preterm birth (<37 weeks gestation) occurs in 10% of all pregnancies worldwide and the optimal way to feed a newborn preterm infant, when breast-feeding is impossible, is not clear. Excessive enteral feeding predisposes to various complications and necrotizing enterocolitis (NEC) that occur in 7% of preterm infants born with less than 1500 g body weight. Early feeding with small volumes of milk is applied to promote GIT maturation and add some nutrients and energy. It is assumed that early feeding allows more rapid advancement to full enteral feeding (EN, e.g 120-160 ml/kg/d) and weaning from parenteral nutrition (PN). This is important to reduce PN-related complications (e.g. sepsis) and to better stimulate body and organ (e.g. gut, brain) development. However, it remains unclear what is the best milk diet when mother's own milk (MM) is not available. Infant formula (IF) and banked human donor milk (DM) are the most frequently used alternatives to MM. MM is superior to IF in promoting feeding tolerance, intestinal function, and NEC resistance in preterm infants. Feeding with DM is also believed to be beneficial, relative to IF, although this pasteurized milk obtained from mothers later in lactation may be less beneficial, relative to the first milk, colostrum. There are differences in the amount and composition between human colostrum and bovine colostrum (BC), but relative to mature human milk, BC contains higher amounts of protein, growth factors and immuno-regulatory components (e.g. immunoglobulins). Large amount of protein in BC provides higher enteral protein intake and may enable a reduction in the use of PN and central venous catheters, and hereby reduced risk of infection. Also this may lead to reduced weight loss and improved growth of the brain and the body. In addition, maturational and NEC-protective effects of BC have repeatedly been documented in preterm pigs when BC is used as the first diet after birth. The investigators therefore plan to investigate whether using BC as nutrition for preterm infants in the first weeks of life is safe, tolerable, and helps to provide nutrients and gut maturation , when MM is not in sufficient amounts or not available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Feeding Intolerance, Extrauterine Growth Retardation, Necrotizing Enterocolitis, Sepsis, Meningitis
Keywords
Preterm infants, Bovine colostrum, Feeding intolerance, Postnatal growth, Intestinal maturation, Necrotizing enterocolitis

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single group for first 12 infants RCT for next 40 infants
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
Arm Title
Colostrum group
Arm Type
Experimental
Arm Description
Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
Intervention Type
Dietary Supplement
Intervention Name(s)
Bovine colostrum
Other Intervention Name(s)
Cow's colostrum
Intervention Description
The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
Primary Outcome Measure Information:
Title
The primary outcome is the tolerability of bovine colostrum feeding
Description
The main purpose of this feasibility pilot study is to investigate whether preterm infants can tolerate bovine colostrum as their first nutrition supplemented to mother's own milk (if available). Presence of feeding intolerance is defined as at any time when feeding is withheld by the neonatologists from day 1-7 and from day 8-14.
Time Frame
From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Outcome Measure Information:
Title
Anthropometry data
Description
Body weight, body length, and head circumference are measured as anthropometry data
Time Frame
Weekly measured from birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Title
Days to regain birth weight
Time Frame
From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Title
Days on parenteral nutrition
Description
Days on PN are the total number of days that a participant receiving any i.v. nutrients other than glucose.
Time Frame
From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Title
Time to full enteral feeding
Description
Full enteral feeding is defined as participants receiving 160ml/kg/d at copenhagen site, or more than 120 ml/kg/d at Chinese sites for a consecutive period of 72 hours.
Time Frame
From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Title
Combined incidence of serious infections and NEC
Description
Serious infections/NEC includes sepsis and meningitis, according the diagnostic criteria at each hospital, and Bell stage II or III NEC.
Time Frame
From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Title
Plasma citrulline level
Description
Citrulline concentration is measured in plasma as a biomarker for absorptive enterocyte mass and/or function
Time Frame
On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Title
Lactase activity and intestinal permeability
Description
Lactase activity and intestinal permeability is measured non-invasively by measuring the urinary ratio of lactulose/lactose, and lactulose/mannitol after the three sugars are administered.
Time Frame
On day 7±1
Other Pre-specified Outcome Measures:
Title
Routine blood tests
Description
Routine blood tests include blood gas analysis, liver enzymes, BUN, creatinine, Na, K, and phosphate.
Time Frame
On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Title
Plasma amino acid composition
Description
Plasma amino acids will be analyzed at each hospital to investigate whether BC feeding provides a normal range of plasma amino acid pattern.
Time Frame
On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Title
Plasma bovine IgG level
Description
The concentration of intact bovine IgG will be measured in the plasma samples from the participants who receive BC supplementation, in order to investigate how much intact bovine IgG is absorbed from the intestine and circulating in the blood. This will only be measured in the participants at RH due to practical reasons.
Time Frame
On day 7±1 at RH for phase A and B
Title
Fecal bovine IgG
Description
The concentration of intact bovine IgG will be measured in the fecal samples from participants who receive BC supplementation, in order to investigate whether bovine IgG can survive digestion.
Time Frame
On day 7±1 at RH & HH and day 7±1 and 14±1 days
Title
Fecal short chain fatty acids (SCFAs)
Description
Fecal SCFAs will be measured as an indicator of bacterial fermentation of the unabsorbed nutrients in the colon.
Time Frame
On day 7±1 at RH & HH and day 7±1 and 14±1 days
Title
Fecal microbiota composition
Description
Microbiota composition in fecal samples will be determined using non-culture-based techniques
Time Frame
On day 7±1 at RH & HH and day 7±1 and 14±1 days

10. Eligibility

Sex
All
Maximum Age & Unit of Time
1 Day
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: FWCH & SBMCH: Preterm infants with birth weights between 1000 and 1800 g, delivered at FWCH & SBMCH, or transferred from other hospitals within 24 h of birth and without any enteral feeding. RH & HH: Preterm infants less than 24 hours of age, between 27+0 and 32+6 weeks of gestation, delivered at RH &HH , or transferred from other hospitals within the first 24 h after birth. Signed parental consent Exclusion Criteria: Major congenital anomalies or birth defects Congenital infection Perinatal asphyxia Gestational age at birth < 28 weeks (FWCH & SBMCH) Extremely SGA infant (weight SD score < -3 SD) Need for mechanical ventilation or cardiovascular support before first BC feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per T. Sangild, PhD
Organizational Affiliation
+45 35 33 26 98
Official's Role
Study Director
Facility Information:
Facility Name
Foshan Women and Children's Hospital (FWCH)
City
Foshan
State/Province
Guangdong
ZIP/Postal Code
528000
Country
China
Facility Name
Shenzheng Baoan Maternity and Child Healthcare Hospital (SBMCH)
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518133
Country
China
Facility Name
Rigshospitalet (RH)
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Hvidovre Hospital (HH)
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark

12. IPD Sharing Statement

Links:
URL
http://neomune.ku.dk/
Description
The current clinical trial is a part of the NEOMUNE project.

Learn more about this trial

Feeding Bovine Colostrum to Preterm Infants

We'll reach out to this number within 24 hrs